MABYLON AG
Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies and neurodegenerative diseases. To identify extremely rare human antibodies Mabylon combines advanced B-cell screening technologies with serum antibody reactivity screens of up to 100’000 human samples a year. Human derived antibodies have the advantage of targeting disease relevant epitopes as exemplified in our most advance programs. In the field of allergy our product MY006, for peanut allergy was shown to inhibit pathological IgE binding to peanut and prevent anaphylaxis in mouse models. In the neuroscience field our lead program for ALS/FTLD targeting TDP-43 has recently been partnered with SciNeuro Pharmaceuticals.
MABYLON AG
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.mabylon.com
Total Employee:
11+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apache Mobile Non Scaleable Content Microsoft Exchange Online
Similar Organizations
ActoBio Therapeutics
ActoBio Therapeutics develops therapeutic agents that treat a number of diseases, primarily on disease areas with high unmet needs.
Alma Bio Therapeutics
Alma goes one step further in the treatment of autoimmune diseases by using body’ own mechanims to restore the original immune balance.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
ESBATech
ESBATech develops fully human antibody fragments for therapeutic applications, applying the single-chain antibody framework.
Galenea
Galenea is engaged in developing therapeutics for central nervous system diseases.
Current Employees Featured
Official Site Inspections
http://www.mabylon.com Semrush global rank: 7.52 M Semrush visits lastest month: 462
- Host name: 94.126.20.68
- IP address: 94.126.20.68
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Mabylon AG"
Biotechnology company | Schlieren | Zürich | Mabylon AG
Mabylon AG is a Swiss biotechnology company leveraging its technology platform and unique know-how to discover and engineer novel antibody therapeutics in allergy, immunology and …See details»
Biotechnology company | Schlieren | Zürich | Mabylon AG
Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies, neurodegenerative diseases, and inflammation. …See details»
Research at Mabylon | Mabylon AG
Mabylon’s objective is to rapidly create high-quality antibody libraries against validated targets from which it selects the best functional, therapeutically developable products. To this aim, Mabylon has access to diverse sources of …See details»
Mabylon AG - Crunchbase Company Profile & Funding
Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies and neurodegenerative diseases. To identify …See details»
Mabylon AG – Swiss Biotech
Mabylon is leading innovation in human-derived antibody therapeutics for severe allergies, inflammation, and neurological disorders. MY006, our first-in-class multi-specific antibody …See details»
Mabylon AG - LinkedIn
Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform...See details»
Mabylon AG Company Profile | Schlieren, ZÜRICH, …
Find company research, competitor information, contact details & financial data for Mabylon AG of Schlieren, ZÃœRICH. Get the latest business insights from Dun & Bradstreet.See details»
Mabylon AG - VentureRadar
Website: https://www.mabylon.com/ Develops innovative therapies using human antibodies to address allergies, neurodegenerative diseases, and inflammation, leveraging extensive …See details»
Mabylon Company Profile 2024: Valuation, Funding
Operator of a biotechnology company intended to harness the therapeutic potential of naturally occurring human antibodies to treat allergies and neurodegenerative diseases.See details»
Harnessing the therapeutic potential of naturally …
Swiss preclinical stage biotech company Mabylon is developing novel human-derived antibody therapeutics to treat allergies and neurological disorders. Neurological disorders, according to the...See details»
Mabylon: Candidate nomination of an anti-allergen …
In collaboration with Pfizer Ignite, Mabylon nominates its anti-allergen multispecific antibody product that is undergoing Investigative New Drug (IND)-enabling studies and subsequent …See details»
About us OnePage | Mabylon AG
Mabylon employees are dedicated professionals with a high degree of specific training and knowledge in a variety of fields such as cellular and molecular immunology, antibody discovery …See details»
Mabylon AG Receives Research Grants Totaling More …
Sep 24, 2024 · Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, …See details»
Mabylon receives over CHF 1.3 million research grants …
Sep 24, 2024 · Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants …See details»
SciNeuro Pharmaceuticals and Mabylon AG to Collaborate …
Oct 26, 2021 · Mabylon AG is a leading Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat neurodegenerative diseases and …See details»
Mabylon receives funding to advance TDP-43 intrabodies …
Sep 27, 2024 · The Swiss biotechnology company Mabylon has received two research grants from Target ALS and the ALS Association to support the development of human-derived …See details»
Mabylon
Swiss preclinical stage biotech company Mabylon is developing novel human-derived antibody therapeutics to treat allergies and neurological disorders. Neurological disorders, according to …See details»
MY006: allergen-targeted antibodies for the treatment of …
Mabylon has developed MY006, a cocktail of patient-derived antibodies for anti-peanut allergen antibody immunotherapy. The lead candidates were selected by Mabylon’s human antibody …See details»
Research programme: Anti-neuroinflammation antibodies
Mabylon are developing anti-neuroinflammation monoclonal antibodies for the treatment of neuroinflammation. Preclinical development is underway in Switzerland.See details»
Research programme: anti-birch pollen allergy antibodies
Mabylon are developing anti-allergy antibodies for the treatment of birch pollen allergies, namely allergic rhinitis and allergic rhinoconjunctivitis.See details»